You just read:

KEYNOTE-024 Three-Year Survival Update: Pembrolizumab Effective as First-Line Therapy for Advanced Non-Small Cell Lung Cancer

News provided by

International Association for the Study of Lung Cancer

Sep 10, 2019, 04:45 ET